Tradestie Institutional Equity Comparison Engine

AKRO vs LLY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LLY Overall Edge

LLY Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eli Lilly & Co. (LLY) driven by superior Valuation, Growth & Margin, Options & Structure while AKRO counters with relative strength in Momentum & Technical. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LLY at 26.5x Forward P/E and 51.2% operating margin (+38.6% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against LLY sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LLY
AKRO N/M vs LLY 26.5x Fwd P/E
Growth & Margin Winner LLY
Op Margin 0.0% vs 51.2% ยท YoY +0.0% vs +38.6%
Momentum & Technical Winner AKRO
1Y +76.8% vs +28.4% ยท 52W Pos 90% vs 80%
Options & Structure Winner LLY
UNCLASSIFIED (30th %ile IV) vs CONSOLIDATION (23rd %ile IV)
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
LLY NYSE
Eli Lilly & Co.
Pharmaceutical Preparations
$1,347.11
-0.3% 1D
Market Cap $1.20T
1M Return +3.09%
1Y Return +28.35%
Forward P/E 26.5x
Unified AI Score
41.4 / 100 SELL
Tech 39.0 Fund 44.0 Flow 67.0 Mom 21.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKRO +76.75% LLY +28.35% Spread: +5.53 pp (AKRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKRO TTM Op. Margin: 0.0% LLY TTM Op. Margin: 51.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs LLY. Trailing 12-month operating profitability (AKRO 0.0% vs LLY 51.2%) and valuation multiples (AKRO N/M vs LLY 26.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKRO (3) vs LLY (7)
Institutional Metric AKRO LLY Criterion Row Winner
Market Capitalization Scale $4.5B $1.20T Larger Scale LLY
Trailing P/E Ratio Valuation N/M 44.9x Lower Multiple LLY
Forward P/E Ratio Valuation N/M 26.5x Lower Multiple LLY
Revenue Growth (YoY) Growth +0.0% +38.6% Higher Growth LLY
Operating Margin (TTM) Profitability 0.0% 51.2% Higher Margin LLY
Net Profit Margin Profitability 0.0% 31.9% Higher Margin LLY
Return on Equity (ROE) Capital Efficiency -34.5% 86.0% Higher ROE LLY
52-Week Range Position Momentum 90% ($21โ€“$58) 80% ($851โ€“$1,475) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.90ฮฒ ยท 2% Vol 0.32ฮฒ ยท 36% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 60.0 / 100 (BUY) 41.4 / 100 (SELL) Higher Composite AKRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKRO vs LLY Buy Guide
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LLY CONSOLIDATION
97d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live LLY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKRO nor LLY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.